SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ICU Medical, Inc. (ICUI) trades at a trailing P/E of 4,121.4, forward P/E of 15.8. Trailing earnings yield is 0.02%, forward earnings yield 6.34%. PEG 1.92. Graham Number is $7.58.
Criteria proven by this page:
- VALUE (31/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 4,121.4); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.02%).
- Forward P/E 15.8 (down from trailing 4,121.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.92 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 0.02% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 6.34% as earnings recover.
- Analyst consensus target $179.00 (+40% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 44/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
31/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ICUI
Valuation Multiples
P/E (TTM)4,121.4
Forward P/E15.8
PEG Ratio1.92
Forward PEG1.92
P/B Ratio1.42
P/S Ratio1.35
EV/EBITDA13.8
Per Share Data
EPS (TTM)$0.03
Forward EPS (Est.)$8.10
Book Value / Share$86.03
Revenue / Share$90.37
FCF / Share$3.63
Yields & Fair Value
Earnings Yield0.02%
Forward Earnings Yield6.34%
Dividend Yield0.00%
Graham Number$7.58
SharesGrow IV$462.61 (+261.8%)
Analyst Target$179.00 (+40%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
37.8 |
1.01 |
3.61 |
6.28 |
- |
| 2017 |
61.7 |
-6.02 |
3.54 |
3.28 |
- |
| 2018 |
172.3 |
-2.78 |
3.93 |
3.54 |
- |
| 2019 |
38.2 |
0.14 |
2.80 |
3.05 |
- |
| 2020 |
51.6 |
-3.42 |
2.99 |
3.53 |
- |
| 2021 |
48.8 |
2.90 |
3.11 |
3.82 |
- |
| 2022 |
-50.6 |
0.31 |
1.80 |
1.65 |
- |
| 2023 |
-81.0 |
1.34 |
1.13 |
1.06 |
- |
| 2024 |
-32.2 |
-0.11 |
1.93 |
1.59 |
- |
| 2025 |
4,802.4 |
-47.73 |
1.66 |
1.58 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$3.66 |
$379.37M |
$63.08M |
16.6% |
| 2017 |
$3.29 |
$1.29B |
$68.64M |
5.3% |
| 2018 |
$1.33 |
$1.4B |
$28.79M |
2.1% |
| 2019 |
$4.69 |
$1.27B |
$101.04M |
8% |
| 2020 |
$4.02 |
$1.27B |
$86.87M |
6.8% |
| 2021 |
$4.74 |
$1.32B |
$103.14M |
7.8% |
| 2022 |
$-3.11 |
$2.28B |
$-74.29M |
-3.3% |
| 2023 |
$-1.23 |
$2.26B |
$-29.66M |
-1.3% |
| 2024 |
$-4.83 |
$2.38B |
$-117.69M |
-4.9% |
| 2025 |
$0.03 |
$2.23B |
$732K |
0% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$8.10 |
$7.99 – $8.19 |
$2.17B |
$2.15B – $2.2B |
6 |
| 2027 |
$9.27 |
$8.83 – $9.68 |
$2.27B |
$2.23B – $2.3B |
6 |
| 2028 |
$10.19 |
$9.27 – $11.10 |
$2.34B |
$2.29B – $2.38B |
2 |
| 2029 |
$10.50 |
$10.34 – $10.68 |
$2.31B |
$2.28B – $2.34B |
1 |
| 2030 |
$11.09 |
$10.92 – $11.28 |
$2.36B |
$2.34B – $2.39B |
1 |
